142 related articles for article (PubMed ID: 26638726)
1. Genetic screening for gynecological cancer: where are we heading?
Manchanda R; Jacobs I
Future Oncol; 2016 Jan; 12(2):207-20. PubMed ID: 26638726
[TBL] [Abstract][Full Text] [Related]
2. Population-based Genetic Testing for Precision Prevention.
Evans O; Manchanda R
Cancer Prev Res (Phila); 2020 Aug; 13(8):643-648. PubMed ID: 32409595
[TBL] [Abstract][Full Text] [Related]
3. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
[TBL] [Abstract][Full Text] [Related]
5. Genetic risk assessment for breast and gynecological malignancies.
Profato JL; Arun BK
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):1-5. PubMed ID: 25502427
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
7. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
[TBL] [Abstract][Full Text] [Related]
8. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
[TBL] [Abstract][Full Text] [Related]
9. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
[TBL] [Abstract][Full Text] [Related]
10. Learning Healthcare System for the Prescription of Genetic Testing in the Gynecological Cancer Risk.
Suárez-Mejías C; Martínez-García A; Martínez-Maestre MÁ; Silvan-Alfaro JM; Moreno Conde J; Parra-Calderón CL
Stud Health Technol Inform; 2017; 235():96-100. PubMed ID: 28423763
[TBL] [Abstract][Full Text] [Related]
11. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
12. Population-based genetic testing for Women's cancer prevention.
Evans O; Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
[TBL] [Abstract][Full Text] [Related]
13. Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
Manchanda R; Lieberman S; Gaba F; Lahad A; Levy-Lahad E
Annu Rev Genomics Hum Genet; 2020 Aug; 21():373-412. PubMed ID: 32315550
[TBL] [Abstract][Full Text] [Related]
14. Genetic risk assessment in breast and gynecologic malignancies- what's to know in 2024?
Kamara D; Silver E; Niell-Swiller M
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):45-50. PubMed ID: 37792522
[TBL] [Abstract][Full Text] [Related]
15. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Barnes-Kedar IM; Plon SE
Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
[TBL] [Abstract][Full Text] [Related]
16. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
18. Hereditary gynecologic cancers: risk assessment, counseling, testing and management.
Ballinger LL
Obstet Gynecol Clin North Am; 2012 Jun; 39(2):165-81. PubMed ID: 22640709
[TBL] [Abstract][Full Text] [Related]
19. The role of genetic testing for cancer susceptibility in gynecologic practice.
Karlan BY; Berchuck A; Mutch D
Obstet Gynecol; 2007 Jul; 110(1):155-67. PubMed ID: 17601911
[TBL] [Abstract][Full Text] [Related]
20. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
